<DOC>
	<DOC>NCT01302899</DOC>
	<brief_summary>The study is designed to primarily assess the effect of aliskiren on albuminuria in patients with non-diabetic nephropathy when treated with ramipril and volume intervention.</brief_summary>
	<brief_title>To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Male and female subjects, age 18 years and above Patients with chronic kidney disease of nondiabetic origin Glomerular filtration rate &gt;30 ml/min/1.73m2 Patients with a history of hypertension and msSBP (mean systolic blood pressure) of &lt;160 mm Hg and msDBP (mean diastolic blood pressure) &lt;105 mm Hg at screening and baseline. Subjects must have a body mass index (BMI) within the range of 18 and 35 kg/m2 Previously treated (within 3 months of screening) with aliskiren or a combination of aliskiren and ramipril. Severe hypertension (msDBP ≥110 mmHg and msSBP ≥180 mmHg) Pregnant or nursing (lactating) women, A medical history of unstable coronary artery disease, myocardial infarction, coronary bypass surgery or cerebrovascular accident within the last six (6) months Diabetes mellitus, Heart failure High rate of renal function loss History of severe hypersensitivity or contraindications to any of the medications or drugs belonging to the similar therapeutic class as the study drugs and the excipients. History of liver disease, positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result. Other protocoldefined inclusion/exclusion criteria applied</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>